MENU×
  1. A Patient Survey of Mobility and Exercise Issues Among MS Patients [poll]. Poll commissioned by: Acorda Therapeutics, Inc. and the Multiple Sclerosis Association of America. February 21, 2008.
  2. Harris Interactive. Talking and Learning to Keep Mobile: A Survey About Difficulty Walking Among People with MS [poll]. Poll commissioned by: Acorda Therapeutics, Inc. and the National MS Society. July 29, 2011.
  3. AMPYRA (dalfampridine) Extended Release Tablets Full Prescribing Information. Acorda Therapeutics, Inc.
  4. Goodman AD, Brown TR, Krupp LB, et al; on behalf of the Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373:732-738.
  5. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68:494-502.
  6. Data on File 00-12. Acorda Therapeutics, Inc.
  7. Data on File 00-15. Acorda Therapeutics, Inc.
  8. Hobart J. “Responder or Nonresponder, That Is the Question.” Was the Responder Definition Used in the Dalfampridine Extended-Release Studies Clinically Meaningful? Poster presented at: AAN Annual Meeting; April 9-16, 2011.
  9. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-item MS walking scale (MSWS-12). Neurology. 2003;60:31-36.
  10. Bethoux F, Bennett S. Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice? Int J MS Care. 2011;13:4-14.
  11. Herndon RM. Pathology and pathophysiology. In: Burks JS, Johnson KP, eds. Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation. New York, NY: Demos Medical Publishing; 2000.
  12. Judge SIV, Lee JM, Bever CT Jr, Hoffman PM. Voltage-gated potassium channels in multiple sclerosis: overview and new implications for treatment of central nervous system inflammation and degeneration. J Rehabil Res Dev. 2006;43:111-122.
  13. Augustine GJ. Voltage-dependent membrane permeability. In: Purves D, Augustine GJ, Fitzpatrick D, et al, eds. Neuroscience. 4th ed. Sunderland, MA: Sinauer Associates Inc; 2008.
  14. Bever CT Jr, Judge SIV. Sustained-release fampridine for multiple sclerosis. Expert Opin Invest Drugs. 2009;18:1013-1024.
  15. Waxman SG, Ritchie JM. Molecular dissection of the myelinated axon. Ann Neurol. 1993;33:121-136.
  16. Blight AR. Brain Res Bull. 1989;22:47-52.
  17. Shi R, Blight AR. Neuroscience. 1997;77:553-562.
  18. Data on File 00-35. Acorda Therapeutics, Inc.
See more

Indication

AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, is the first and only brand medication indicated to improve walking in adults with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

Important Safety Information

AMPYRA is contraindicated in patients with history of seizure, moderate or severe renal impairment (CrCl ≤ 50 mL/min), or history of hypersensitivity to AMPYRA or 4-aminopyridine.

Indication

AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, is the first and only brand medication indicated to improve walking in adults with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

Important Safety Information

  • AMPYRA is contraindicated in patients with history of seizure, moderate or severe renal impairment (CrCl ≤ 50 mL/min), or history of hypersensitivity to AMPYRA or 4-aminopyridine.
  • AMPYRA can cause seizures. The risk of seizures increases with increasing doses. Permanently discontinue AMPYRA if seizure occurs. In the post-marketing period seizures have been reported. The majority of seizures occurred at the recommended dose, in patients without a history of seizures, and generally within days to weeks of starting therapy.
  • AMPYRA has not been evaluated in patients with history of seizures or with epileptiform activity on an EEG, as these patients were excluded from clinical trials. The risk of seizures in patients with epileptiform activity on an EEG is unknown, and could be substantially higher than that observed in clinical studies.
  • Avoid concomitant use of AMPYRA with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same. Instruct patients to discontinue use of any product containing 4-AP prior to initiating AMPYRA to reduce the potential for dose-related adverse reactions.
  • AMPYRA can cause anaphylaxis and severe allergic reaction. Signs and symptoms included respiratory compromise, urticaria, and angioedema of the throat or tongue. If an anaphylactic or other serious allergic reaction occurs, permanently discontinue AMPYRA.
  • AMPYRA is cleared predominantly by the kidneys. The risk of seizures in patients with mild renal impairment (CrCl 51–80 mL/min) is unknown, but AMPYRA plasma levels in these patients may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures. Estimated CrCl should be known before initiating AMPYRA and monitored at least annually during treatment.
  • The most common adverse reactions (incidence ≥ 2% and at a rate greater than placebo) for AMPYRA in MS patients were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, MS relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain.
  • The risk of adverse reactions, including seizures, increases with increasing AMPYRA doses. There is no evidence of additional benefit at doses greater than 10 mg twice daily.
  • Concomitant use with OCT2 inhibitors (e.g., cimetidine) may cause increased exposure to AMPYRA and potential risk of seizures.
  • There are no adequate data on AMPYRA in pregnant women. Based on animal data, use of AMPYRA during pregnancy may cause fetal harm.
  • There are no data on presence of AMPYRA in breastmilk; benefits of breastfeeding should be considered along with benefit of AMPYRA to the mother and potential risks to the infant.
  • Safety and effectiveness of AMPYRA in patients younger than 18 years have not been established.
  • Clinical studies of AMPYRA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Because elderly patients are more likely to have decreased renal function, it is important to know the estimated CrCl before initiating AMPYRA.

Please see the Full Prescribing Information.